Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Inclusion Criteria: * At least 50 years of age. * Fulfilling ACR/EULAR classification criteria for PMR newly diagnosed or treatment resistant. * No GCs or GCs \<15 mg/day since at least 15 days prior to planned randomization. * PMR-AS-CRP \>17. * Absence of other inflammatory arthropathy, connective tissue diseases or vasculitis. * Able to give informed consent. * French health insurance holder Exclusion Criteria: * Clinical evidence of giant cell arteritis. * Uncontrolled high blood pressure or cardiovascular disease. * High risk of VTE because of a history of VTE (DVT and/or PE) within 12 weeks prior to randomization or a history of recurrent (\>1) VTE (counting co-occurring DVT+PE as 1 single event). * Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR * Planned major surgical procedure during the study or medical history, blood abnormalities or any clinical condition that compromises inclusion. * Current smoker if age \>65 years. * Current active uncontrolled infection. * Treatment by probenecid. * Alkaline phosphatase (ALP) ≥2 x ULN. * Total bilirubin level (TBL) ≥1.5 x ULN. * Neutropenia (absolute neutrophil count \<1000 cells/uL) (\<1.00 x 103/uL or \<1.00 GI/L). * Lymphopenia (lymphocyte count \<500 cells/uL) (\<0.50 x 103/uL or \<0.50 GI/L). * Patient under court protection or protected adults